ShanXi C&Y Pharmaceutical Group Co.,LTD. Company Description

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Fluoxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Montmorillonite powder, Varenicline tartrate tablets, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as salt acid glucosamine raw material product.

It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services.

The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to ShanXi C&Y Pharmaceutical Group Co.,LTD.

in September 2014. The company was founded in 2005 and is based in Datong, China.

ShanXi C&Y Pharmaceutical Group Co.,LTD.

Country	China
Founded	2005
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,196
CEO	Qun Zhao

Contact Details

Address: No. 1378, Heng'an Street Datong, 037010 China
Phone	86 35 2611 6426
Website	cy-pharm.com

Stock Details

Ticker Symbol	300254
Exchange	Shenzhen Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE1000016D0
SIC Code	2834

Key Executives

Name	Position
Qun Zhao	President and Director
Yanjie He	Financial Director
Ying Min Yu	Chief Engineer
Junxian Yu	Secretary, Vice President and Non-Independent Director
Bao Ping Gu	Vice President
Kai Rui Luo	Vice President